Literature DB >> 29987513

[Avoidance-endurance fast screening (AE-FS) : Content and predictive validity of a 9‑item screening instrument for patients with unspecific subacute low back pain].

S V Wolff1, R Willburger2, D Hallner3, A C Rusu3, H Rusche4, T Schulte2, M I Hasenbring3.   

Abstract

BACKGROUND: Among screening measures to assess psychosocial risk factors (yellow flags) for chronic low back pain (LBP) economic tools which address dysfunctional endurance pain responses besides emotional distress and fear-avoidance pain processing are rare. Targeting contrasting types of pain processing might improve stratified patient counselling.
OBJECTIVE: The aim of the study was to develop a short screening method, based on the avoidance-endurance model of pain and to investigate the prognostic validity for pain intensity, disability and physical function.
MATERIAL AND METHODS: A prospective observational study was carried out on 144 patients with subacute LBP (<3 months) from 7 general practitioners and 5 orthopedic practices. The 9‑item avoidance-endurance fast screening (AE-FS) was derived from a previous 37-item screening using correlational and receiver operating curve (ROC) analyses and the agreement of subgrouping was calculated using Cohen's kappa. Primary outcomes were assessed after 6 months by mail in 124 patients (86%). Endpoints were pain intensity and disability.
RESULTS: The classification of subgroups as high and low risk by both measures had considerable agreement with a value of 0.71 (Cohen's Kappa). The sensitivity to predict pain intensity >2 was high (82%) as was the positive predictive value (80%) but the negative predictive value was moderate (61%). The ROC (AUC) characteristics (95% confidence interval CI) were 0.70 (0.60-0.80) for pain intensity and for limitations in the pain disability index (PDI) 0.70 (0.55-0.87). DISCUSSION: The 9‑item AE-FS displayed sufficient prognostic validity for all three outcomes in a sample of primary care patients with subacute LBP. The differentiation of the high-risk patients into fear-avoidance and endurance-related pain processing enables the physician to provide an individualized counselling with the aim of a healthy balance between stress and relaxation.

Entities:  

Keywords:  Avoidance-endurance; Prognosis; Psychosocial; Screening; Subacute low back pain

Mesh:

Year:  2018        PMID: 29987513     DOI: 10.1007/s00482-018-0310-x

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  26 in total

1.  Cut-off points for mild, moderate, and severe pain on the visual analogue scale for pain in patients with chronic musculoskeletal pain.

Authors:  Anne M Boonstra; Henrica R Schiphorst Preuper; Gerlof A Balk; Roy E Stewart
Journal:  Pain       Date:  2014-09-17       Impact factor: 6.961

2.  The value of tailored communication for person-centred outcomes.

Authors:  Sandra van Dulmen
Journal:  J Eval Clin Pract       Date:  2010-11-18       Impact factor: 2.431

Review 3.  Fear and anxiety in the transition from acute to chronic pain: there is evidence for endurance besides avoidance.

Authors:  Monika I Hasenbring; Omar Chehadi; Christina Titze; Nina Kreddig
Journal:  Pain Manag       Date:  2014

4.  Pain-related avoidance versus endurance in primary care patients with subacute back pain: psychological characteristics and outcome at a 6-month follow-up.

Authors:  Monika I Hasenbring; Dirk Hallner; Bernhard Klasen; Irmgard Streitlein-Böhme; Roland Willburger; Herbert Rusche
Journal:  Pain       Date:  2011-11-16       Impact factor: 6.961

5.  Classification of psychosocial risk factors (yellow flags) for the development of chronic low back and leg pain using artificial neural network.

Authors:  Dirk Hallner; Monika Hasenbring
Journal:  Neurosci Lett       Date:  2004-05-06       Impact factor: 3.046

6.  Fear-avoidance- and endurance-related responses to pain: development and validation of the Avoidance-Endurance Questionnaire (AEQ).

Authors:  Monika I Hasenbring; Dirk Hallner; Adina C Rusu
Journal:  Eur J Pain       Date:  2008-12-19       Impact factor: 3.931

7.  [Endurance strategies-a neglected phenomenon in the research and therapy of chronic pain?].

Authors:  M Hasenbring
Journal:  Schmerz       Date:  1993-12       Impact factor: 1.107

8.  [Assessing disability in chronic pain patients.].

Authors:  U Dillmann; P Nilges; H Saile; H U Gerbershagen
Journal:  Schmerz       Date:  1994-06       Impact factor: 1.107

9.  Trajectories and predictors of the long-term course of low back pain: cohort study with 5-year follow-up.

Authors:  Ying Chen; Paul Campbell; Victoria Y Strauss; Nadine E Foster; Kelvin P Jordan; Kate M Dunn
Journal:  Pain       Date:  2018-02       Impact factor: 7.926

10.  Core outcome measurement instruments for clinical trials in nonspecific low back pain.

Authors:  Alessandro Chiarotto; Maarten Boers; Richard A Deyo; Rachelle Buchbinder; Terry P Corbin; Leonardo O P Costa; Nadine E Foster; Margreth Grotle; Bart W Koes; Francisco M Kovacs; C-W Christine Lin; Chris G Maher; Adam M Pearson; Wilco C Peul; Mark L Schoene; Dennis C Turk; Maurits W van Tulder; Caroline B Terwee; Raymond W Ostelo
Journal:  Pain       Date:  2018-03       Impact factor: 6.961

View more
  3 in total

1.  Individual recovery expectations and prognosis of outcomes in non-specific low back pain: prognostic factor review.

Authors:  Jill A Hayden; Maria N Wilson; Richard D Riley; Ross Iles; Tamar Pincus; Rachel Ogilvie
Journal:  Cochrane Database Syst Rev       Date:  2019-11-25

2.  [Interdisciplinary pain psychology II : Risk factors, diagnostic workup, therapy and transfer in clinical practice].

Authors:  M I Hasenbring; R Klinger; K Thieme
Journal:  Schmerz       Date:  2018-08       Impact factor: 1.107

Review 3.  [Psychosocial risk factors for chronic back pain in the general population and in competitive sports : From theory to clinical screening-a review from the MiSpEx network].

Authors:  M I Hasenbring; C Levenig; D Hallner; A-K Puschmann; A Weiffen; J Kleinert; J Belz; M Schiltenwolf; A-C Pfeifer; J Heidari; M Kellmann; P-M Wippert
Journal:  Schmerz       Date:  2018-08       Impact factor: 1.107

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.